BioMarin made over $1 billion in sales last quarter, growing 32% compared to last year.

Nov 2, 2026, 7:25 PM ETResultsRead the original at prnewswire.com

Good for BMRN

BioMarin reported 32% sales growth and more than $1 billion in quarterly sales, with VOXZOGO up 12%. Its pipeline programs remain in development, but the reported sales growth supports a stronger outlook.

BMRN · BioMarin Pharmaceutical Inc.

AI read · Good for BMRN

The AI's read

The wider portfolio after buying Amicus and rising global demand help explain the growth. VOXZOGO reached more countries, and BioMarin reported progress on 2 programs still in development. Those programs have not yet shown sales benefits, but the reported sales growth is the clearest sign in this report.

Get alerts for BMRN

Follow BioMarin Pharmaceutical Inc. (BMRN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMRN

Free on the App Store and Google Play, or on the web.